Press

Novamind Has Applied to Have its Common Shares Posted for Trading on the OTCQB in the United States

Jul 21 • 3 min read

Quick Take: Novamind, a psychedelic medicine company, has applied to have its common shares traded on the OTCQB in the US Novamind Inc. (CSE: NM) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, is pleased to announce that it has submitted its application to have its common shares posted for…

Levitee Labs to Commence Trading on the Canadian Securities Exchange Under the Ticker Symbol “LVT”.

Jul 20 • 3 min read

Quick Take: Levitee Labs has been listed on the Canadian Securities Exchange Levitee Labs Inc. (CSE: LVT) is pleased to announce that it has received final approval from the Canadian Securities Exchange (“CSE“) to list its common shares on the CSE. At the opening of the market on July 21, the common shares of Levitee…

Knowde Group Inc. Enters Into a Strategic Partnership with LMC Manna Research to Drive Quality and Collaboration in the Conduct of Cannabis and Psychedelic Clinical Trials.

Jul 19 • 5 min read

Quick Take: Knowde Group, a hybrid research and consulting organization specializing in cannabis and psychedelics, has entered a partnership with LMC Manna Knowde Group Inc.™, the decentralized Global Contract Research Organization and hybrid consultancy specializing in cannabis and psychedelic research, announced today that it entered into a Strategic Partnership with LMC Manna Research, the largest…

Global Wellness Strategies and Cannvalate AU Sign Revolutionary Psychedelic Deal

Jul 19 • 3 min read

Quick Take: Global Wellness Strategies has signed a binding letter of intent with Cannvalate to acquire their wholly owned subsidiary, Shanti Therapeutics. Global Wellness Strategies Inc. (formerly Redfund Capital Corp.) (CSE: LOAN) is pleased to announce it has signed a binding letter of intent (“BLOI”) on July 12, 2021 with Cannvalate Pty Ltd (“CVL”) based in Australia to…

Nova Mentis Appoints Dr. Stephen Glazer as Director and Chief Science Officer

Jul 16 • 3 min read

Quick Take: Nova Mentis Life Science has appointed a new Chief Science Officer, Dr. Stephen Glazer Nova Mentis Life Science Corp. (CSE: NOVA), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce the appointment of Dr. Stephen Glazer as Director, Chief Science Officer. “We’re proud to welcome Dr….

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435